Ex vivo gene therapy is a promising approach to orthopedic regenerative medicine, but the unregulated production of osteoinductive molecules has also resulted in abnormal bone formation and tumorigenesis. To address these limitations, Gersbach et al. (Gene Therapy, Vol. 13, pp. 873-882) describe a retroviral system to deliver the Runx2 osteoblastic transcription factor. Their results present a novel system for regulating osteoblastic differentiation of a clinically relevant autologous cell source, which is significant to developing controlled and effective orthopedic gene therapy strategies and studying the regulation of osteoblastic differentiation.
Dr AJ García, Petit Institute for Bioengineering and Bioscience, 315 Ferst Drive, Room 2314, Atlanta, GA 30332-0363, USA. E-mail: email@example.com
Abstract available online.
(C) Gene Therapy.
Posted by: Tressie Dalaya.
Message posted by: Trevor M. D'Souza